With the seminal discovery in dry AMD and dry eye pathogenesis, we aim to translate the scientific breakthrough into ophthalmic products that meet the unmet clinical needs. The goal is to launch several Traditional Chinese Medicine products in China and to advance small molecule projects into clinical stage worldwide. In ophthalmology field, we strive to become the leader in China and a competitor of the world.
Small molecule immune-oncology
Focusing on a novel immune-oncology target that is highly pursued by global pharmaceutical companies, we aim to maintain the lead position in pharmacology research and drug development. At the same time, we are expanding the indication into infectious diseases (antiviral) and strive to become the leading innovator in this field.
Focusing on the application of gene editing of a novel target in immunotherapy, we aim to maintain the lead position in clinical applications and strive to become a global competitor in this field.
Focusing on establishing a world class medical aesthetics R&D platform and integrating innovation with marketing insight, we aim to apply our deep understanding of Chinese consumers and distribution channels to share the dividends of the social progress and consumption upgrade in china, and strive to become the leader in medical aesthetics in China.
Leveraging the cutting-edge biomedical research achievements and the deep insight into pet medicine market in China, we aim to establish a strong product pipeline and quickly establish ourselves as the leader in Chinese pet medicine market.